While there have been trials addressing VEGFA treatment for cerebrovascular diseases, a majority of clinical trials using VEGFA pro-angiogenic therapy have been conducted in coronary artery related dysfunctions [67,68,72]. Here, VEGFA is linked to cerebrovascular disorder.